Changes in the Leadership of Helix Polska AURORA,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Changes in the Leadership of Helix Polska

AURORA, ON--(Marketwired - Feb 4, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces changes in the leadership team of its Polish subsidiary "Helix Polska." The appointments are effective as of January, 28, 2016.

Dr. Zbigniew Markowski, CEO of Helix Biopharma Corp., has been appointed Chairman of the Board of Helix Polska supported by two additional Board members, Dr. Marek Orlowski and Prof. Slawomir Majewski. Dr. Pawel Wisniewski has been appointed CEO of Helix Polska. Helix Polska operates out of Warsaw, Poland and it is planned to become the Company`s Scientific Research and Clinical Development Unit in Europe.

" Dr. Orlowski is one of the few leading figures in Biotech in Poland, " said Dr. Markowski, " and we are very proud to have him on board and are very grateful for his strong input into Helix Polska."

Dr. Orlowski is currently a CEO of Adiuvo S.A., an investment holding company domiciled in Poland. Adiuvo invests in biomedicine and medical technologies. Dr. Orlowski has previously acted as a consultant for Sanofi Aventis for portfolio development and globalization of brands, a position he had held since 2010. Dr. Orlowski is the co-founder of the Polish pharmaceutical company, Nepentes S.A., which was acquired by Sanofi-Aventis in 2010. He is a board member and Chief Executive Officer of Airway Medix Sp. z.o.o., a Polish-Israeli company that produces ventilation assistance devices for intensive care units. Dr. Orlowski holds a MD (Medical Director) degree from the Medical Academy of Warsaw.

Dr. Heman Chao, Chief Scientific Officer of Helix BioPharma Corp., said, " Now that we have the right leadership team in place, I am very excited to leverage the huge potential of our DOS47 technology platform in Poland. "

About Helix Polska

Helix Polska is a fully-owned subsidiary of Helix BioPharma Corp. specializing in the pre-clinical development and basic research in the field of cancer therapies. Helix Polska will support its parental company in an early stage development of the new products based on DOS47 technological platform. Currently, Helix Polska is developing a novel molecule v-DOS47, targeting breast cancer, in accordance with the license agreement signed in December 2015. v-DOS47 is a first drug candidate that will be developed by Helix BioPharma Corp. outside Canada. In the future, next products will enter Helix Polska's pipeline, as the Company hopes to benefit from funding grants from both Poland and the European Union.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward- looking information") within the meaning of applicable Canadian securities laws. Forward-looking information means disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to Helix's future business, operations, research and development, including the Helix Polska's development activities relating to v-DOS47 and other information in future periods. Forward-looking information includes, without limitation, those statements relating to the nature, means of funding, coordination of and benefits to be derived from the development activities expected to be undertaken by Helix Polska and other information in future periods. Forward-looking information may be identified by words including, without limitation, "believe", "will", "expected", "hopes", "may" and other similar expressions, are intended to provide information about management's current plans and expectations regarding the conduct of the development activities of Helix Polska and the other operations of Helix.

Although Helix believes that the expectations reflected in such forward-looking information are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation: (i) the inherent uncertainty involved in scientific research and drug development; (ii) future expenditures, the insufficiency of the Company's current cash resources and the need to secure additional financing on terms satisfactory to Helix or at all, including the risk that Helix Polska may be unable to secure non-dilutive financing sufficient to fund all or any part of its development activities; (iii) that Helix Polska's development activities do not proceed on the timelines anticipated or at all, including that the results of such development activities will not justify future clinical development or provide the anticipated benefits to the DOS47 platform as a whole; and (iv) those risks and uncertainties affecting Helix as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at  www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking information, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking information.

Forward-looking information is based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations: Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Fax: (905) 841-2244 Email: ir@helixbiopharma.com Web: www.helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 65

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 40

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 33

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 159

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 47

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 23

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 116

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading

Top 5 Most Recently Viewed Articles

Elisa and Sensofusion Launch Joint Drone Venture in Europe

Updated Category News Views 293

A Match Made Beneath the Clouds Woke up today thinking about the bizarre world of drones, and it looks like Elisa Corporation and Sensofusion Plc are paving a new path in the skies of Europe. The two firms have locked hands to form Masthead Oy, aimed at creating a bird’s-eye defense mechanism to manage the unruly swarm of drones buzzing around Finland and Estonia. The...

Continue Reading
Innovative Alfapump Use in Elective Hernia Repair Highlights Benefits

Updated Category News Views 191

Innovative Solutions for Managing Ascites Managing ascites is vital, especially for patients encountering surgical options. Ascites, characterized by the accumulation of fluid in the abdomen, often complicates surgical procedures like umbilical hernia repairs. A significant number, about 20%, of individuals suffering from ascites due to liver cirrhosis are affected by...

Continue Reading
Kibu Unveils Insightful Cybersecurity Threat Report Series

Updated Category News Views 152

Kibu Unveils New Cybersecurity Threat Report Series Today, Kibu has announced the launch of an insightful quarterly threat report series that focuses on emerging challenges in the realm of cybersecurity. This new initiative aims to provide security teams with valuable insights derived from real-world scenarios and case studies, fully equipping them to tackle the evolving...

Continue Reading
Baidu Faces Securities Fraud Lawsuit: Key Investor Alert

Updated Category News Views 99

Stormy Weather for Baidu Investors Digging through the latest on Baidu's (NASDAQ:BIDU) unsettling journey feels like watching a rerun of a soap opera you wish would just end. The company has been slapped with a class action lawsuit by The Law Offices of Frank R. Cruz, accusing them of pulling the wool over investors' eyes from November 18, 2025, to August 17, 2026....

Continue Reading
Forecasting Earnings: What to Expect from IGC Pharma

Updated Category News Views 133

IGC Pharma's Approaching Earnings Announcement IGC Pharma (AMEX: IGC) is poised to disclose its quarterly earnings soon. Investors are looking forward to understanding the company's financial health and how it positions itself for the future. In the lead-up, it's vital to grasp the expectations that analysts have set. Analyst Estimates and Earnings Predictions Experts in...

Continue Reading